Rabbit Anti-Human CD105/Endoglin
Slide this table
|Clone Nr.||Rabbit IgG|
|Reconstitution||Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml.|
|Stability and Storage||The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.|
|Antigen||Recombinant human sCD105/Endoglin (RT #S01-025)|
|Application||WB, E, FC, IF|
|Synonyms||Endoglin; END; ORW; HHT1; ORW1; CD105|
|Description||Endoglin, also known as CD105, is a Type I integral membrane glycoprotein with a large, disulfide-linked, extracellular region and a short, constitutively phosphorylated, cytoplasmic tail. Two splice variants of human endoglin, the S-endoglin and L-endoglin that differ in the length of their cytoplasmic tails have been identified. Endoglin is highly expressed on vascular endothelial cells, chondrocytes, and syncytiotrophoblasts of term placenta. It is also found on activated monocytes, bone marrow pro-erythroblasts, and leukemic cells of lymphoid and myeloid lineages. Human and mouse endoglin share approximately 70% and 97 % amino acid sequence identity in their extracellular and intracellular domains, respectively. It has clearly been shown that CD105/Endoglin is required for angiogenesis and it plays a key role in heart development. Mutations in human endoglin or ALK-1 (another type I serine/threonine receptor) lead to the vascular disorder hereditary hemorrhagic telangiectasia (HHT). Mice heterozygous for endoglin have been developed as disease models for HHT. Endoglin has been shown to be a powerful marker of neovascularization. It is also useful as a functional marker that defines long-term repopulating hematopoietic stem cells.|
- B lymphocyte compartments in the human splenic red pulp: capillary sheaths and periarteriolar regions. B.S. Steiniger et al., Histochem Cell Biol. 2014 May;141(5):507-18.
- Elevated expression of VEGFR-3 in lymphatic endothelial cells from lymphangiomas. S. Norgall et al., BMC Cancer. 2007; 7: 105.
All prices plus VAT + possible delivery charges